What is your background and what have you done before joining Follicum?
I have more than 25 years of experience from various positions in high-tech start-up companies, particularly from the innovation environments around Lund University and Malmö University, Ideon Innovation and MINC incubator. I have also worked with more mature companies, such as CEO for the privately held investment company AB Axel Granlund in Malmö for 8 years. I have extensive experience in evaluating small and medium-sized enterprises in various stages of development, particularly from when I was a business developer and CEO of Teknopol AB in Lund. During the time at Teknopol I worked, for example, with companies such as Polar Rose, Dignitana, and Galenica. More recently I served as CFO in Zaplox during their IPO in the first half of 2017. Today I am the managing director of Swedish Growth Fund which is the largest owner in Follicum.
Why did you join Follicum as a Board Member?
Follicum is in a very interesting phase of its development, targeting an area that is forgotten by the larger pharmaceutical companies – hair growth. Not very many new drugs have been introduced concerning hair growth even though it is an area with a large potential turnover. The recent achievement that Follicum has developed a topical formulation is especially impressive as it is very challenging to develop peptide based topical formulations. The early stage diabetes project is also exciting and promising. The connection between the hair and diabetes project can be hard to spot at first glance but there is a biological explanation. All in all, it looks exciting and I am very pleased to be able to follow the progress and be part of the development. Follicum has always delivered on time according to plan which is very impressive. I am glad to join the professional team around Follicum.
What expertise will you bring to the Follicum Board?
I have a lot of experience in building and growing companies within different areas, and with this comes experience in financing of these companies. I know a lot about the problems that growing companies can run into and hopefully how to avoid and solve these problems. I am a certified board member of Styrelseakademin, The Swedish Academy of Board Directors, and have served on several boards of directors, both as a member and chairman.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 (0)46 – 19 21 97
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com